POLE ultra-mutated endometrial cancer and immunotherapy
It is my understanding that if a cancer has high mutation burden (like lung, melanoma) they are better candidates for immunotherapies. As far as I know ovarian cancer is a low mutation burden type of cancer and hence typically may have limitations in targeted therapies. Here is an article discussing that.
Up until now I have only seen the presence of Micro Satellite Instability (MSI) being discussed as an indication of whether or not immunotherapies would work for endometrial cancer patients. I found out that there is another group. If the genomic profiling of your tumour has POLE exonuclease domain mutations (10% of the EC patients have this) and you are experiencing a recurrence, it seems you would be a good candidate for immunotherapy. Here are a few papers.. If you have the POLE mutation please check with your doctor to see if you qualify for an immunotherapy.
https://www.ncbi.nlm.nih.gov/pubmed/27362548
https://www.ncbi.nlm.nih.gov/pubmed/28427513
https://www.sciencedirect.com/science/article/pii/S0959804917311462
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 121.2K Cancer specific
- 2.8K Anal Cancer
- 440 Bladder Cancer
- 306 Bone Cancers
- 1.6K Brain Cancer
- 28.4K Breast Cancer
- 391 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 12.9K Head and Neck Cancer
- 6.3K Kidney Cancer
- 666 Leukemia
- 789 Liver Cancer
- 4.1K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 235 Multiple Myeloma
- 7.1K Ovarian Cancer
- 53 Pancreatic Cancer
- 486 Peritoneal Cancer
- 5.3K Prostate Cancer
- 1.2K Rare and Other Cancers
- 532 Sarcoma
- 718 Skin Cancer
- 647 Stomach Cancer
- 190 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.8K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards